Drug Trial Radar · NCT00007189
Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
Last checked: Nov 19, 2026Latest source record: Oct 19, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,625
Actual
Start
Jan 2001
Primary completion
May 2007
Sponsor
- Lead sponsor
- Seattle Institute for Biomedical and Clinical ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Aging (NIA); VA Puget Sound Health Care System; University of Washington; Johns Hopkins University
- First posted
- Dec 14, 2000
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.
Conditions
- Alzheimer Disease
Interventions
Naproxen Sodium (Aleve)Drug
Celecoxib (Celebrex)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Sun Health Research Institute
Sun City, Arizona
Roskamp Institute Memory Clinic, 10770 N. 46th Street
Tampa, Florida
Johns Hopkins University
Baltimore, Maryland
Boston University School of Medicine
Boston, Massachusetts
University of Rochester
Rochester, New York
Veterans Affairs Puget Sound Health Care System, University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.